标题:Expression of phosphatase of regenerating liver-3 is associated with prognosis of Wilms' tumor
作者:Sun, Fengyin; Li, Wenyi; Wang, Lie; Jiao, Changfeng
作者机构:[Sun, Fengyin] Shandong Univ, Qilu Hosp, Dept Pediat Surg, Jinan, Shandong, Peoples R China.; [Li, Wenyi; Wang, Lie] Nanjing Command PLA, Fuzhou Gen 更多
通讯作者:Li, WY
通讯作者地址:[Li, WY]Xinzhou City Peoples Hosp, Dept Vasc Surg, 156 North Xierhuan Rd, Xinzhou 034000, Shanxi Province, Peoples R China.
来源:ONCOTARGETS AND THERAPY
出版年:2017
卷:10
页码:311-317
DOI:10.2147/OTT.S107076
关键词:Wilms' tumor; prognosis; tumorigenesis; recurrence
摘要:Objective: The current study was undertaken to explore the clinical and prognostic value of phosphatase of regenerating liver-3 (PRL-3) expression in Wilms' tumor.; Methods: Seventy-six patients with Wilms' tumor in Qilu Hospital from January 2003 to July 2009 were enrolled in the study. Protein expression level of PRL-3 was examined by immunohistochemical staining, and the correlation between PRL-3 expression and histopathological parameters, clinical variables, and outcome of patients with Wilms' tumor were analyzed.; Results: We found that 19% of patients with unfavorable histology had tumor recurrence and 16% of patients died following the operation. PRL-3 was expressed in 15 out of 76 tumors (19%) and expressed highly in unfavorable histology Wilms' tumor (P=0.04). PRL-3 protein expression level was correlated to 2.5-fold increase in recurrence rate of Wilms' tumor (P=0.06) without any statistically significant difference. However, in favorable histology Wilms' tumor, PRL-3 expression was correlated to an increase of 3.4-fold in recurrence rate (P=0.03).; Conclusion: The expression of PRL-3 protein was correlated with an increased recurrence rate of favorable histology Wilms' tumor. PRL-3 may serve as a promising biomarker for predicting patients with high risk of Wilms' tumor. Further investigations are warranted to investigate the clinical function of PRL-3 in Wilms' tumor.
收录类别:SCOPUS;SCIE
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85010383415&doi=10.2147%2fOTT.S107076&partnerID=40&md5=4b990f67ebb28b410aaa30a4d5e2f196
TOP